ConductScience.org, home

Paper39587494

Light-chain amyloidosis with concomitant symptomatic myeloma (CRAB-SLiM features): clinical characteristics, cytogenetic abnormalities, and outcomes.

Yu C and 7 others. BMC Cancer, 2024. Cited by 5 papers, by iCite.

Cite this record

ConductScience Library. Light-chain amyloidosis with concomitant symptomatic myeloma (CRAB-SLiM features): clinical characteristics, cytogenetic abnormalities, and outcomes. Papers, record 39587494. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39587494

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Light-chain amyloidosis with concomitant symptomatic myeloma (CRAB-SLiM features): clinical characteristics, cytogenetic abnormalities, and outcomes.
PubMed
Journal
BMC Cancer
PubMed
Year
2024
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
5
iCite
Relative citation ratio, by iCite
1.09, provisional
iCite
Revised in PubMed
2024-11-28
PubMed

Authors8

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Yu CChenqi
2Li JJing
3Xu TTianhong
4Wang WWenjing
5Yang YYang
6Zhou CChi
7Wang PPu
8Liu PPeng

Source PubMed

Download CSV of authors

Topics12

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Multiple MyelomaMajor topic
Immunoglobulin Light-chain AmyloidosisMajor topic
Chromosome AberrationsMajor topic
Humans
Female
Male
Aged
Middle Aged
Retrospective Studies
Prognosis
Aged, 80 and over
Adult

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
22ZR1411400Natural Science Foundation of ShanghaiPubMed

Source PubMed

Download CSV of grants

References40

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
123541011Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013.Mayo Clin Proc2013https://conductscience.org/library/papers/23541011PubMed
230104177Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p.Clin Lymphoma Myeloma Leuk2018https://conductscience.org/library/papers/30104177PubMed
337968258Outcomes of t(11;14) light chain (AL) amyloidosis after autologous stem cell transplantation: benchmark for new therapies.Blood Cancer J2023https://conductscience.org/library/papers/37968258PubMed
423091105New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers: impact on survival outcomes.J Clin Oncol2012https://conductscience.org/library/papers/23091105PubMed
527257181Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study.Blood2016https://conductscience.org/library/papers/27257181PubMed
635429180Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment.Am J Hematol2022https://conductscience.org/library/papers/35429180PubMed
723432783The prognostic value of diagnosing concurrent multiple myeloma in immunoglobulin light chain amyloidosis.Br J Haematol2013https://conductscience.org/library/papers/23432783PubMed
836779691Impact of cytogenetic abnormalities on treatment outcomes in patients with amyloid light-chain amyloidosis: subanalyses from the ANDROMEDA study.Amyloid2023https://conductscience.org/library/papers/36779691PubMed
936652935Systemic Light Chain Amyloidosis, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.J Natl Compr Canc Netw2023https://conductscience.org/library/papers/36652935PubMed
1023456262Molecular pathogenesis of multiple myeloma: basic and clinical updates.Int J Hematol2013https://conductscience.org/library/papers/23456262PubMed
1133594045Minimal residual disease negativity by next-generation flow cytometry is associated with improved organ response in AL amyloidosis.Blood Cancer J2021https://conductscience.org/library/papers/33594045PubMed
1226240224Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group.J Clin Oncol2015https://conductscience.org/library/papers/26240224PubMed
1330327369Cytogenetic intraclonal heterogeneity of plasma cell dyscrasia in AL amyloidosis as compared with multiple myeloma.Blood Adv2018https://conductscience.org/library/papers/30327369PubMed
1429482381Bone marrow plasma cell infiltration in light chain amyloidosis: impact on organ involvement and outcome.Amyloid2018https://conductscience.org/library/papers/29482381PubMed
1512393530Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis.Blood2003https://conductscience.org/library/papers/12393530PubMed
1620194151Clinical features and treatment response of light chain (AL) amyloidosis diagnosed in patients with previous diagnosis of multiple myeloma.Mayo Clin Proc2010https://conductscience.org/library/papers/20194151PubMed
1732010993Impact of minimal residual negativity using next generation flow cytometry on outcomes in light chain amyloidosis.Am J Hematol2020https://conductscience.org/library/papers/32010993PubMed
1834517412How I treat AL amyloidosis.Blood2022https://conductscience.org/library/papers/34517412PubMed
1925439696International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.Lancet Oncol2014https://conductscience.org/library/papers/25439696PubMed
2016715110Multiple myeloma-associated AL amyloidosis: is a distinctive therapeutic approach warranted?Bone Marrow Transplant2006https://conductscience.org/library/papers/16715110PubMed

See all 40 referencesDownload CSV of references

Cited by3

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 5 citations.

PMIDTitleJournalYearIn PapersSource
42807240Periorbital hyperpigmentation as the initial manifestation of smoldering multiple myeloma in a patient with coexisting gastrointestinal stromal tumor: a case report and narrative literature review.Front Oncol2026https://conductscience.org/library/papers/42807240PubMed
42278643Multiple Myeloma Concomitant with AL Amyloidosis: Histopathological Aspects of the Common Plasma Cell Spectrum.Int J Mol Sci2026https://conductscience.org/library/papers/42278643PubMed
41452481Bortezomib combined with autologous stem cell transplantation overcomes cytogenetic abnormalities in AL amyloidosis.Int J Hematol2026https://conductscience.org/library/papers/41452481PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/39587494

GET https://conductscience.org/api/papers/v1/39587494/references?page=2